Chimerix presents preclinical data showing antiviral activity of Brincidofovir
Chimerix announced data from two preclinical studies which assessed the in vivo antiviral activity of brincidofovir against polyomavirus. These studies are part of the company's ongoing effort to develop antivirals in high unmet medical need areas, including hematopoietic cell transplant and solid organ transplant patient populations. These two studies evaluated BCV's effect against MuPyV, a mouse polyomavirus closely related to the human BK virus. In these studies, mice with MuPyV were treated with BCV either 24 hours after being infected or prophylactically for a full week prior to infection. Data from the two studies show that BCV demonstrated significant antiviral activity against MuPyV and showed no safety signals across BCV doses administered. In mice treated after infection with MuPyV, BCV delivered via intraperitoneal injection once daily, twice weekly or once weekly reduced kidney viral loads by 100-fold relative to those that received placebo, while administration prophylactically showed that BCV 20 mg/kg or higher decreased viral load in the kidney by approximately 10-fold.